Table 1.
Demographic characteristics of study patients.
| Characteristics | Patients (n = 243) |
|---|---|
| Age, years; median (interquartile range, IQR) | 45 (41–48) |
| Gender | |
| Female, n (%) | 54 (22) |
| Male, n (%) | 189 (78) |
| Body mass index, kg/m2, median (IQR) | 20 (19–22) |
| HCV RNA, log10 IU/mL, median (IQR) | 6.0 (5.4–6.5) |
| HCV genotype | |
| 1a, n (%) | 10 (4) |
| 1b, n (%) | 60 (25) |
| 2a, n (%) | 4 (2) |
| 3a, n (%) | 36 (15) |
| 3b, n (%) | 53 (22) |
| 6a, n (%) | 65 (27) |
| 6e, n (%) | 2 (1) |
| 6n, n (%) | 11 (5) |
| 6v, n (%) | 2 (1) |
| Previous HCV treatment | |
| No, n (%) | 220 (91) |
| Yes, n (%) | 23 (9) |
| Interferon plus ribavirin, n (%) | 21/23 (91) |
| Pegylated interferon plus ribavirin, n (%) | 2/23 (9) |
| Response to previous HCV treatment | |
| Non-responder, n (%) | 5/23 (22) |
| Relapse or breakthrough, n (%) | 12/23 (52) |
| Early treatment discontinuation, n (%) | 3/23 (13) |
| Unknown, n (%) | 3/23 (13) |
| HCV/HIV transmission | |
| PWID, n (%) | 153 (63) |
| MSM, n (%) | 19 (8) |
| Heterosexuals, n (%) | 44 (18) |
| Unknown, n (%) | 27 (11) |
| Duration of ART | |
| ≤1 year | 5 (2) |
| 1–3 years | 24 (10) |
| 3–5 years | 34 (14) |
| >5 years | 180 (74) |
| Undetectable HIV RNA, n (%) | 239 (98) |
| CD4+ count, cells/mm3, median (IQR) | 452 (313–623) |
| CD4/CD8 ratio, median (IQR) | 0.6 (0.4–0.9) |
| Hemoglobin, g/L, median (IQR) | 150 (137–160) |
| Platelets, 109/L, median (IQR) | 198 (164–253) |
| ALT, IU/L, median (IQR) | 56 (39–72) |
| AST, IU/L, median (IQR) | 46 (34–65) |
| Albumen, g/L, median (IQR) | 46 (44–48) |
| Total bilirubin, μmol/L, median (IQR) | 10 (7–14) |
| eGFR, ml/min/1.73m2, median (IQR) | 112 (97–125) |
| FIB-4 score, median (IQR) | 1.43 (0.95–2.08) |
| FIB-4 score categories, n (%) | |
| <1.45 | 126 (52) |
| 1.45–3.25 | 97 (40) |
| >3.25 | 20 (8) |
Data are presented as No. (%) unless otherwise specified.
Abbreviations: IQR, interquartile range; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PWID, people who inject drugs; MSM, men who have sex with men; ART, antiretroviral therapy; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, Fibrosis 4 marker.